Key TakeawaysUK’s NICE recommends Wegovy (NVO) for cardiovascular risk reduction in adults with obesity, paving the way for NHS integration by late April.U.S. Treasury rushes to launch a digital portal to process $166 billion in refunds for Trump-era tariffs recently ruled unlawful by the Supreme Court.Microsoft (MSFT) and Engine No. 1 are in exclusive talks for a $7 billion natural gas power project in Texas to support data centers.Australia’s S&P/ASX 200 surged 1.6% in early trade as Treasurer Chalmers pr ...

British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Wegovy presentation is displayed in New Columbia, Pennsylvania, U.S., November 13, 2023. REUTERS/Hannah Beier/Illustration/File Photo Purchase Licensing Rights, opens new tab April 1 (Reuters) - UK's drug cost-effectiveness watchdog has recommended Novo Nordisk's (NOVOb.CO), opens new tabWegovy to reduce the risk of serious h ...

Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug development in ways that are beginning to reshape how fast new medicines reach patients.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Compl ...

[music] We're back on Morning Trade Live. Let's focus on Novo Nordisk, the company announcing a new drug subscription [music] plan today. More on that in a second with Marley.But the chart has been nothing short of a disaster. The stock is trading near four-year lows and is [music] down more than 75% from its all-time high in late June of 2024. Look at that.So, that's the focus of the morning trade. Joining us now for a closer look, as we promised, is Marley. Good morning, Marley.just walk us through the de ...

The company is trying to win customers by offering a "lower, predictable monthly price†for its obesity drugs. ...

Novo Nordisk (NVO) on Tuesday announced a first-of-its-kind subscription program for its weight loss therapy Wegovy (semaglutide) available on telehealth platforms, including LifeMD (LFMD) and Hims & Hers (HIMS). As part of the program, cash-paying patients can choose 3-, 6-, or 12-month subscriptions ...

Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, "predictable" monthly prices. Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name. Longer plans offer lower monthly pricing, and the company expects people to save up to $1,200 a year on the injection and as much as $600 a year ...

Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo Purchase Licensing Rights, opens new tab LONDON, March 31 (Reuters) - Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients payin ...

Reporting by Yagnoseni Das in Bengaluru; Editing by Devika Syamnath Our Standards: The Thomson Reuters Trust Principles., opens new tab Purchase Licensing Rights Business Novo Nordisk further slashes prices of Ozempic, Wegovy in India to better compete as generics enter | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams Purchase ...

整理 | GLP1减重宝典内容团队 但现在，行业开始转向另一个问题。真正决定下一轮竞争格局的，未必只是最强疗效，而是谁能够成为更多患者进入治疗体系的第一 步。 诺和诺德判断，到2030年，口服剂型将拿下全球超过三分之一的肥胖市场，这意味着在大药厂眼里，口服已经不再只是注射剂之外的补 充选项，而是未来市场基础盘的重要组成部分。 这背后最关键的变化，在于肥胖药市场正在从单纯的疗效竞争，转向入口竞争。 对大量患者而言，减重治疗最大的门槛，并不总是疗效是否足够强，而是是否愿意真正开始。有人对注射始终存在心理障碍，有人很难 接受长期每周打针的治疗方式，也有人虽然有减重意愿，但并没有准备好一开始就进入强干预状态。相较之下，口服药更接近日常慢病 管理的习惯，也更容易被视为一种可以尝试、可以持续、可以融入生活的选择。 这正是口服剂型最重要的商业意义。它改变的不是天花板，而是地板。它首先争夺的，不是那批最重度、最复杂、最需要强化治疗的人 群，而是那些原本可能根本不会进入减重药物治疗体系的人。只要这部分人群被大规模带进来，整个市场的底盘就会被重新抬高。 过去几年，肥胖药市场最受关注的问题一直是谁更强。谁能把减重幅度做得更高，谁能 ...